X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs PIRAMAL ENTERPRISES - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE PIRAMAL ENTERPRISES CADILA HEALTHCARE/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 31.7 36.1 87.8% View Chart
P/BV x 5.9 3.0 196.4% View Chart
Dividend Yield % 0.8 0.8 98.4%  

Financials

 CADILA HEALTHCARE   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-17
PIRAMAL ENTERPRISES
Mar-17
CADILA HEALTHCARE/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs4602,095 22.0%   
Low Rs3051,025 29.8%   
Sales per share (Unadj.) Rs92.1492.8 18.7%  
Earnings per share (Unadj.) Rs14.872.6 20.4%  
Cash flow per share (Unadj.) Rs18.594.7 19.5%  
Dividends per share (Unadj.) Rs3.2021.00 15.2%  
Dividend yield (eoy) %0.81.3 62.1%  
Book value per share (Unadj.) Rs68.0862.5 7.9%  
Shares outstanding (eoy) m1,023.74172.56 593.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.23.2 131.2%   
Avg P/E ratio x25.821.5 120.1%  
P/CF ratio (eoy) x20.716.5 125.6%  
Price / Book Value ratio x5.61.8 311.0%  
Dividend payout %21.628.9 74.6%   
Avg Mkt Cap Rs m391,581269,194 145.5%   
No. of employees `00016.94.0 420.0%   
Total wages/salary Rs m15,00217,939 83.6%   
Avg. sales/employee Rs Th5,594.521,190.3 26.4%   
Avg. wages/employee Rs Th890.14,470.1 19.9%   
Avg. net profit/employee Rs Th899.93,120.0 28.8%   
INCOME DATA
Net Sales Rs m94,29585,037 110.9%  
Other income Rs m1,2862,338 55.0%   
Total revenues Rs m95,58187,374 109.4%   
Gross profit Rs m19,03634,991 54.4%  
Depreciation Rs m3,7503,817 98.2%   
Interest Rs m45020,310 2.2%   
Profit before tax Rs m16,12213,202 122.1%   
Minority Interest Rs m3381,699 19.9%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3-100 3.0%   
Tax Rs m1,2892,281 56.5%   
Profit after tax Rs m15,16812,520 121.1%  
Gross profit margin %20.241.1 49.1%  
Effective tax rate %8.017.3 46.3%   
Net profit margin %16.114.7 109.3%  
BALANCE SHEET DATA
Current assets Rs m60,22387,590 68.8%   
Current liabilities Rs m53,058185,578 28.6%   
Net working cap to sales %7.6-115.2 -6.6%  
Current ratio x1.10.5 240.5%  
Inventory Days Days7031 225.0%  
Debtors Days Days8848 185.4%  
Net fixed assets Rs m72,984108,523 67.3%   
Share capital Rs m1,024345 296.7%   
"Free" reserves Rs m68,576148,481 46.2%   
Net worth Rs m69,600148,826 46.8%   
Long term debt Rs m24,684144,957 17.0%   
Total assets Rs m152,207482,394 31.6%  
Interest coverage x36.81.7 2,231.9%   
Debt to equity ratio x0.41.0 36.4%  
Sales to assets ratio x0.60.2 351.4%   
Return on assets %10.36.8 150.8%  
Return on equity %21.88.4 259.0%  
Return on capital %17.912.0 150.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m21,28015,001 141.9%   
Fx outflow Rs m10,8745,150 211.2%   
Net fx Rs m10,4069,851 105.6%   
CASH FLOW
From Operations Rs m13,495-100,393 -13.4%  
From Investments Rs m-29,103-24,202 120.3%  
From Financial Activity Rs m23,158135,705 17.1%  
Net Cashflow Rs m7,55611,110 68.0%  

Share Holding

Indian Promoters % 74.8 52.9 141.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 4.0 207.5%  
FIIs % 5.9 26.6 22.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 16.5 66.7%  
Shareholders   44,069 93,274 47.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  BIOCON LTD  IPCA LABS  NATCO PHARMA  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Feb 22, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 8-QTR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS